Dermatoloxía
Servizo
Carlos
Ferrándiz Foraster
Publicacións nas que colabora con Carlos Ferrándiz Foraster (46)
2021
-
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort
Acta dermato-venereologica, Vol. 101, Núm. 1, pp. adv00354
-
Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study
European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382
-
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis
Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517
-
Sentinel lymph node biopsy vs. Observation in thin melanoma: A multicenter propensity score matching study
Journal of Clinical Medicine, Vol. 10, Núm. 24
2020
-
Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760
-
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150
-
The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study
Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741
2019
-
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364
-
Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study
Cancer Medicine, Vol. 8, Núm. 9, pp. 4235-4244
-
Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population
British Journal of Dermatology
2018
-
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study
Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800
-
Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016
Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 617-623
2017
-
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1700-1708
-
Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts
Medicine (United States), Vol. 96, Núm. 26
-
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 6, pp. 1021-1028
-
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321
-
Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries
Journal of the American Academy of Dermatology, Vol. 76, Núm. 2, pp. 299-308.e16
-
Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts
British Journal of Dermatology, Vol. 176, Núm. 3, pp. 643-649
2016
-
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209
-
Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis
Journal of Investigative Dermatology, Vol. 136, Núm. 3, pp. 593-602